BBIO — BridgeBio Pharma Share News
0.000.00%
Last trade - 00:00- $13.12bn
- $15.77bn
- $502.08m
U.S. STOCKS ON THE MOVE-Bruker Corp, Centuri Holdings, Shoe Carnival
US FDA program favorable for rare disease drug developers, says Jefferies
U.S. RESEARCH ROUNDUP-BOK Financial, Sable Offshore, Zscaler
Brief: Helix Acquisition Corp. II Retains More Than 60% Of Trust Account
BridgeBio Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: BridgeBio Pharma Q2 Net Income USD -183.758 Million
Brief: Novel Human Genetics Evidence Confirms Estimates Of Genetic Prevalence, Underdiagnosis, And Potentially Greater Symptom Burden Of Gain-Of-Function CASR Variants Associated With ADH1
U.S. RESEARCH ROUNDUP-Best Buy, Chevron, Soundhound Ai
Brief: BridgeBio Raises $300 Mln Through Partial Capped Monetization Of Beyonttra European Royalty
BridgeBio Pharma gains after H.C. Wainwright raises PT
Brief: Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
BridgeBio rises as sales of heart disease drug drive quarterly revenue beat
U.S. RESEARCH ROUNDUP-Coca-Cola, Ecolab, Honeywell
BridgeBio gains as Q1 sales of heart condition drug beat estimates
BridgeBio Pharma Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: BridgeBio Pharma Q1 Net Income USD -169.608 Million Vs. IBES Estimate USD -179.7 Million
Brief: Beyonttra™ (Acoramidis), The First Near-Complete TTR Stabilizer (≥90%), Approved in Japan To Treat ATTR-CM
U.S. STOCKS ON THE MOVE-SurgePays, B. Riley, CarMax
U.S. STOCKS ON THE MOVE-OrganiGram, Phillips 66, SurgePays